OrbiMed

Thank you Kyle LaHucik, at Endpoints News, for covering the launch of Belenos Biosciences, our new biotech startup in partnership with KeyMed Biosciences. Belenos is led by CEO Donnie McGrath, an OrbiMed Venture Partner & former BioShin CEO. https://lnkd.in/ec_4Gi-U

We are excited to publicly announce the launch of Exsilio Therapeutics, a biotech developing redosable genomic medicines for a broad range of diseases. Exsilio means leap (Latin), and this leap in genomic medicine would not be possible without the work of Roy Amariglio, the principal on our private equity team who founded the company. Together with Tal Zaks, a partner on our private equity team who joined as Chairman and CEO, and with the funding of several other investors, Exsilio is now well positioned to advance its genomic medicines. https://lnkd.in/eGKG8re4

Tomorrow, Tal Zaks, an OrbiMed Partner & former Chief Medical Officer of Moderna, will share his thoughts with The National Academies of Sciences, Engineering, and Medicine. Based on his experience as a drug developer and investor, Tal will share his insights on what it takes to better align investments in innovation with addressing unmet needs and improving health outcomes. Tune in on Tuesday, June 18th at 11:00 am ET here: https://lnkd.in/ehJfzQm3

Congratulations to our portfolio company PROTEOLOGIX Inc on entering a definitive agreement to be acquired by Johnson & Johnson for $850 million upfront plus a potential milestone payment! OrbiMed co-incubated PROTEOLOGIX Inc in 2021 and was one of the company’s largest investors. PROTEOLOGIX Inc is focused on developing bispecific antibodies for immune-mediated diseases, with lead programs targeting significant unmet medical needs in atopic dermatitis (eczema) and other indications. Read more here: https://lnkd.in/eUa9HSCV

Exciting M&A news! Genmab is set to acquire our portfolio company ProfoundBio for $1.8bn, expanding its oncology portfolio with promising antibody-drug conjugate technologies and clinical candidates, including the novel, next-gen Rina-S for #ovariancancer. https://lnkd.in/eby29f-6

Congratulations to our portfolio company Fusion Pharmaceuticals for being acquired by AstraZeneca! The deal of up to $2.4B helps the fight against cancer with next generation radioconjugates as precision medicine, including a clinical stage radioconjugate targeting PSMA for prostate cancer. https://t.co/5O2h0RMpKi

Congrats to our portfolio company Amolyt Pharma on its agreement to be acquired by AstraZeneca with an $800M upfront payment & potential $250M milestone! Exciting news for AstraZeneca's rare disease portfolio & Amolyt Pharma's therapeutic peptide pipeline. https://lnkd.in/ejXx6KWk

Thanks to our friends at Cambridge Associates for speaking with Managing Partner Carl Gordon about OrbiMed’s exciting investments in Alzheimer’s disease, including our portfolio company Leal Therapeutics. We are working hard to seek meaningful progress for Alzheimer’s patients and successful returns for our partners. Listen here: https://ow.ly/eYCw50QBgoy #UnseenUpside

Congratulations to OrbiMed portfolio company ArriVent Biopharma on pricing its upsized #IPO of 9.7 million shares at $18.00 per share! The company raised ~$175 million in gross proceeds and is now trading under the symbol "AVBP" on Nasdaq. https://t.co/65c1OSwMVX

OrbiMed is excited to partner with Nanotronics investing in their proprietary tech to advance quality control & and precision manufacturing in #healthcare and #biotech. Read more here:https://lnkd.in/eVA7u2iY